News
-
-
-
COMMUNIQUÉ DE PRESSE
Viromed Medical AG: ViroCAP® med successfully completes regulatory process as a Class IIa medical device – starting signal for market launch at the European Wound Congress 2026
Viromed Medical AG announces ViroCAP® med's successful completion of the regulatory process as a Class IIa medical device, paving the way for market launch at the European Wound Congress 2026. Cold plasma technology for wound treatment -
-
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Viromed Medical AG missed revenue forecast for 2025 financial year, but continued to grow significantly and achieved a positive result; revised forecast for 2026
Viromed Medical AG missed revenue forecast for 2025 but saw significant growth, achieving a positive result. The company has revised its forecast for 2026 due to market launch delays -
-
-
COMMUNIQUÉ DE PRESSE
Viromed Medical AG starts production of the OEM version of ViroCAP® for HELLMUT RUCK GmbH
Viromed Medical AG starts production of the OEM version of ViroCAP® for HELLMUT RUCK GmbH, marking an exclusive partnership in podiatry with access to over 120,000 customers and preparations for further international sales cooperations -
